NCT04757311已完成不适用
The Treatment Choices, Duration and Outcomes in Patients With Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
Istanbul Medeniyet University1 个研究点 分布在 1 个国家目标入组 1,750 人开始时间: 2020年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,750
- 试验地点
- 1
- 主要终点
- Percentage of use anti-EGFR agents
研究概览
简要总结
The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
详细描述
In this study, with the given rationale is to reveal treatment approaches, survival data, side effect profile and their management in our country in RAS WT mCRC patients by means of the real-world data collection.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have been histologically diagnosed with mCRC
- •Patients over the age of 18
- •Patients receiving at least a cycle systemic treatment for metastatic disease
- •RAS wild type patients
- •Patients who has demographic, histopathological and clinical information
排除标准
- •Patients diagnosed as mCRC but only referred to BSC
- •Patients with RAS mutation
- •Patients who were included in any clinical trial except standard treatments during their treatment
结局指标
主要结局
Percentage of use anti-EGFR agents
时间窗: throughout of treatment, 3 years
The anti-EGFR agent selection
Progression Free Survival (PFS)
时间窗: 3 years treatment
PFS three years after initiation of treatment with anti-EGFR agents
次要结局
- Advers events(throughout of treatment, 3 years)
研究者
Mahmut Gumus
Mahmut Gumus, MD, Professor Medical Oncolgy
Istanbul Medeniyet University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.OrganoidsMetastatic CancerColon CancerNCT04906733D1 Medical Technology (Shanghai) Co., Ltd, China80
已完成
不适用
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)Prostatic NeoplasmsNCT02230059Janssen Research & Development, LLC382
已完成
不适用
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyMelanomaNCT02780089Bristol-Myers Squibb408
Unknown
3 期
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerColorectal Cancer MetastaticNCT01910610GERCOR - Multidisciplinary Oncology Cooperative Group464
进行中（未招募）
2 期
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerProstate CancerNCT02452008Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60